Our findings indicate that RNF25 is overexpressed in various cancer types and contributes to resistance against various small molecule inhibitors, particularly apoptosis-inducing agents like gemcitabine and docetaxel, suggesting a previously unexplored mechanism underlying drug resistance. This evidence concerns the gene RNF25 and cancer.